BRAIN Biotech Aktie
| 2,75EUR | -0,05EUR | -1,79% |
WKN DE: 520394 / ISIN: DE0005203947
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 279 | 288 | 309 | 309 | 307 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,14 | 0,13 | 0,16 | 0,18 | 0,18 |
Bilanz (in Mio. EUR) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 33 | 39 | 30 | 25 | 46 |
| Summe Anlagevermögen | 39 | 39 | 48 | 45 | 43 |
| Summe Aktiva | 72 | 78 | 78 | 71 | 89 |
Bilanz (in Mio. EUR) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 46 | 36 | 44 | 48 | 75 |
| Summe Eigenkapital | 26 | 42 | 34 | 23 | 14 |
| Summe Passiva | 72 | 78 | 78 | 71 | 89 |
Adresse
| Darmstädter Strasse 34-36, 64673 Zwingenberg | |
| Telefon | +49 (6251) 9331-0 |
| Internet | http://www.brain-biotech.de |
Management
|
Alexander Pelzer
VP, Head-Research & Development |
|
Anna Carina Eichhorn
Vice Chairman-Supervisory Board |
|
Christine Uekert
Independent Member-Supervisory Board |
|
Erik de Vries
Chief Executive Officer |
|
Florian Schnabel
Independent Member-Supervisory Board |
|
Martin Langer
EVP & Managing Director-BioScience Operations |
|
Martina Schuster
Head-Investor Relations |
|
Michael Majerus
Chairman-Supervisory Board |
|
Michael Schneiders
Chief Financial Officer |
|
Stephen Catling
Independent Member-Supervisory Board |
|
Thomas Kessler
Executive Vice President & Unit Head-Cosmetics |
|
Ute Dechert
Vice President-Human Resources & Processes |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.